pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG
BRIGHT MINDS BIOSCIENCES
BRIGHT MINDS BIOSCIENCES INC.
Bright Minds Biosciences is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker DRUG. Primary therapeutic focus areas include Cocaine-Related Disorders, Cocaine Dependence, Nicotine Depen
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
- Status
- Public
- HQ
- 19 Vestry St, New York, NY 10013, US
- Employees
- 12
- Programs
- 1063
- Drugs
- 444
- Patents
- 57
Semaglutide Pen Injector
Phase 2 · small molecule · Opioid Use Disorder
Semaglutide Pen Injector for Opioid Use Disorder is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Internal code STUDY00024676
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BRIGHT MINDS BIOSCIENCES INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Opioid Use Disorder
- Status
- active
- Trials
- 1